# Gene Therapy for Patients With Transfusion-Dependent β-Thalassemia

> **NCT07721480** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Prince of Wales Hospital, Shatin, Hong Kong** · enrollment: 6 (estimated)

## Conditions studied

- Beta Thalassemia Transfusion Dependent

## Interventions

- **DRUG:** HGI-001 Injection

## Key facts

- **NCT ID:** NCT07721480
- **Lead sponsor:** Prince of Wales Hospital, Shatin, Hong Kong
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09
- **Primary completion:** 2028-12
- **Final completion:** 2030-12
- **Target enrollment:** 6 (ESTIMATED)
- **Last updated:** 2026-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07721480

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07721480, "Gene Therapy for Patients With Transfusion-Dependent β-Thalassemia". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07721480. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*